Abstract
Guided by co-crystal structures of compounds 15, 22 and 30, an SBDD approach led to the discovery of the 6-methyl pyridone series as a novel class of GKAs that potently activate GK in enzyme and cell assays. Anti-diabetic OGTT efficacy was demonstrated with 54 in a mouse model of type 2 diabetes.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Crystallography, X-Ray
-
Diabetes Mellitus, Experimental / drug therapy
-
Diabetes Mellitus, Experimental / enzymology*
-
Disease Models, Animal
-
Drug Design*
-
Enzyme Activation / drug effects
-
Enzyme Activators / administration & dosage
-
Enzyme Activators / chemistry
-
Enzyme Activators / pharmacology*
-
Glucokinase / metabolism*
-
Glucose Tolerance Test
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology*
-
Mice
-
Mice, Inbred C57BL
-
Mice, Obese
-
Models, Molecular
-
Molecular Structure
-
Pyridones / administration & dosage
-
Pyridones / chemistry
-
Pyridones / pharmacology*
-
Structure-Activity Relationship
Substances
-
Enzyme Activators
-
Hypoglycemic Agents
-
Pyridones
-
Glucokinase